JPWO2012023562A1 - 移植片の評価方法 - Google Patents
移植片の評価方法 Download PDFInfo
- Publication number
- JPWO2012023562A1 JPWO2012023562A1 JP2012529601A JP2012529601A JPWO2012023562A1 JP WO2012023562 A1 JPWO2012023562 A1 JP WO2012023562A1 JP 2012529601 A JP2012529601 A JP 2012529601A JP 2012529601 A JP2012529601 A JP 2012529601A JP WO2012023562 A1 JPWO2012023562 A1 JP WO2012023562A1
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- multinucleation
- multinucleating
- ability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011156 evaluation Methods 0.000 title abstract description 9
- 238000002054 transplantation Methods 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 36
- 210000004027 cell Anatomy 0.000 claims description 97
- 210000005088 multinucleated cell Anatomy 0.000 claims description 32
- 210000004683 skeletal myoblast Anatomy 0.000 claims description 22
- 238000001514 detection method Methods 0.000 claims description 18
- 238000004113 cell culture Methods 0.000 claims description 17
- 238000004364 calculation method Methods 0.000 claims description 11
- 238000010191 image analysis Methods 0.000 claims description 11
- 238000003384 imaging method Methods 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 210000003855 cell nucleus Anatomy 0.000 claims description 5
- 238000010899 nucleation Methods 0.000 claims description 3
- 210000004940 nucleus Anatomy 0.000 description 27
- 238000011282 treatment Methods 0.000 description 21
- 101100515524 Dictyostelium discoideum myoB gene Proteins 0.000 description 14
- 230000006870 function Effects 0.000 description 12
- 206010019280 Heart failures Diseases 0.000 description 10
- 210000000805 cytoplasm Anatomy 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 7
- 101150110078 myoA gene Proteins 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001172 regenerating effect Effects 0.000 description 5
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 3
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 3
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 201000005180 acute myocarditis Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 102000043525 human CXCL12 Human genes 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Abstract
Description
これらの原因と重症度に応じて弁形成術や置換術、冠動脈バイパス術、左室形成術、機械的補助循環などが適用される。
重症心筋梗塞等においては、心筋細胞が機能不全に陥り、さらに線維芽細胞の増殖、間質の線維化が進行し心不全を呈するようになる。心不全の進行に伴い、心筋細胞は傷害されてアポトーシスに陥るが、心筋細胞は殆ど細胞分裂をおこさないため、心筋細胞数は減少し心機能の低下もさらに進む。
このような重症心不全患者に対する心機能回復には細胞移植法が有用とされ、既に自己骨格筋芽細胞による臨床応用が開始されている。
(1)多核化する機能を有する細胞を含む移植用試料の移植適格性を評価する方法であって、前記多核化する機能を有する細胞が多核化する能力を表す指標である多核化能を求めることを含む、前記方法。
(2)多核化能を求めることが、
(i)1または2以上の前記移植用試料の一部を個々の細胞に解離するステップ、
(ii)(i)で解離した細胞を播種し、インキュベートするステップ、および
(iii)(ii)でインキュベートした細胞培養物中の多核細胞を検出するステップ、
を含み、求めた多核化能と予め設定された閾値とを比較することを含む、(1)の方法。
(4)多核化能が、多核化率である、(1)〜(3)の方法。
(5)多核化する機能を有する細胞が、骨格筋芽細胞であり、求める多核化能が、多核化率であり、該多核化率が予め設定された閾値よりも大きい場合、心臓移植用に好適であると評価する、(1)〜(3)の方法。
(6)多核化する機能を有する細胞を含む移植用試料の移植適格性を評価するためのシステムであって、多核細胞を検出するための検出部、および多核化能を求めるための計算部を含む、前記システム。
(8)画像解析部が、染色された細胞を撮像する撮像部を含み、該画像解析部による解析が、前記撮像部により撮像された細胞画像中の細胞領域および細胞核領域を区分することを含む、(7)のシステム。
本発明における移植用試料は、典型的には培養した細胞および/またはその産生物で構成されるが、生体の所定部(例えば患部等)を補填および/または支持するための各種の材料(補填材料や支持材料)なども含む。移植用試料は、典型的には哺乳動物、例えば、ヒトや家畜等の疾病、傷病の治療等に用いられるものであるが、これに限定されるものではない。移植片の形状は特に限定されず、例えばシート状、膜状、塊状、柱状等の種々の形状であってよい。本発明において移植用試料といった場合、1の移植片を意味してもよいし、複数の移植片からなる移植片の集団を意味してもよい。移植片の集団は、典型的には例えば同一ロットで製造された移植片の集団などが挙げられるが、これに限定されるものではない。
(i)1または2以上の移植用試料の一部を個々の細胞に解離するステップ、
(ii)(i)で解離した細胞を播種し、インキュベートするステップ、および
(iii)(ii)でインキュベートした細胞中の多核細胞を検出するステップ、
を含む。
上記ステップ(i)において、試料の一部を個々の細胞にバラバラに解離する。解離する方法は当業者に十分知られた方法を用いることができ、典型的にはトリプシン処理などが挙げられるが、これに限定されるものではない。後続のステップのため、ステップ(i)の処理に起因する細胞へのダメージは極力少ないことが望まれる。
本発明の一態様において、骨格筋芽細胞のシート状細胞培養物を評価する。骨格筋芽細胞は、近年心臓の再生医療に有用な移植用細胞と考えられており、そのシート状細胞培養物は、移植片として好適に用いられる。
条件1:画像中の核の数が100個以下
条件2:画像中の核の数が1個以上
条件3:画像中の細胞のない領域の占める面積が50%未満
条件4:画像中に細胞のない領域、細胞質及び核以外の領域が存在しない
の全てに当てはまるもののみを実際に分析する画像とし、いずれかに当てはまらないものは分析不可として消去し、次の観察視野を撮像する。なお、本態様では、細胞は細胞質部分と、核部分とを区別して染色することができる。
骨格筋芽細胞のシート状細胞培養物の多核化率を調べるため、二種類のシート状細胞培養物(SheetAおよびSheetB)を調製し、以下のプロトコルにしたがって多核化率を計測した。
骨格筋芽細胞のシート状細胞培養物を酵素処理し、単核の骨格筋芽細胞に完全に解離させた。SheetAを解離させて得られた骨格筋芽細胞をmyoA、SheetBを解離させて得られた骨格筋芽細胞をmyoBとした。解離させた細胞をカルチャースライドに播種し、CO2インキュベーターにカルチャースライドを入れ、37℃、5%CO2の条件で14〜22時間培養した。
続いて、二種類の骨格筋芽細胞からなるシート状細胞培養物SheetAおよびSheetBのサイトカイン産生量を測定した。測定キットには、Quantikine Human VEGF(R&D Systems社製)、Quantikine Human CXCL12/SDF-1α(R&D Systems社製)、RayBio Human HGF ELISA(RayBiotech,Inc社製)を用いた。測定は各キット付属のプロトコールに従って実施した。
Claims (8)
- 多核化する機能を有する細胞を含む移植用試料の移植適格性を評価する方法であって、前記多核化する機能を有する細胞が多核化する能力を表す指標である多核化能を求めることを含む、前記方法。
- 多核化能を求めることが、
(i)1または2以上の前記移植用試料の一部を個々の細胞に解離するステップ、
(ii)(i)で解離した細胞を播種し、インキュベートするステップ、および
(iii)(ii)でインキュベートした細胞培養物中の多核細胞を検出するステップ、
を含み、求めた多核化能と予め設定された閾値とを比較することを含む、請求項1に記載の方法。 - 多核化する機能を有する細胞が、骨格筋芽細胞である、請求項1または2に記載の方法。
- 多核化能が、多核化率である、請求項1〜3のいずれか一項に記載の方法。
- 多核化する機能を有する細胞が、骨格筋芽細胞であり、求める多核化能が、多核化率であり、該多核化率が予め設定された閾値よりも大きい場合、心臓移植用に好適であると評価する、請求項1〜3のいずれか一項に記載の方法。
- 多核化する機能を有する細胞を含む移植用試料の移植適格性を評価するためのシステムであって、多核細胞を検出するための検出部、および多核化能を求めるための計算部を含む、前記システム。
- 検出部が、撮像された細胞画像を解析する画像解析部を有する、請求項6に記載のシステム。
- 画像解析部が、染色された細胞を撮像する撮像部を含み、該画像解析部による解析が、前記撮像部により撮像された細胞画像中の細胞領域および細胞核領域を区分することを含む、請求項7に記載のシステム。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012529601A JP5657674B2 (ja) | 2010-08-17 | 2011-08-17 | 移植片の評価方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010182142 | 2010-08-17 | ||
JP2010182142 | 2010-08-17 | ||
JP2012529601A JP5657674B2 (ja) | 2010-08-17 | 2011-08-17 | 移植片の評価方法 |
PCT/JP2011/068587 WO2012023562A1 (ja) | 2010-08-17 | 2011-08-17 | 移植片の評価方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2012023562A1 true JPWO2012023562A1 (ja) | 2013-10-28 |
JP5657674B2 JP5657674B2 (ja) | 2015-01-21 |
Family
ID=45605215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012529601A Active JP5657674B2 (ja) | 2010-08-17 | 2011-08-17 | 移植片の評価方法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US9909161B2 (ja) |
EP (1) | EP2607898B1 (ja) |
JP (1) | JP5657674B2 (ja) |
CN (1) | CN102869988B (ja) |
WO (1) | WO2012023562A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6284862B2 (ja) * | 2014-09-17 | 2018-02-28 | 富士フイルム株式会社 | 細胞配置決定装置および方法並びにプログラム |
CN116134148A (zh) * | 2020-09-30 | 2023-05-16 | 泰尔茂株式会社 | 用于判定骨骼肌成肌细胞的多核化状态的系统 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007528755A (ja) * | 2003-08-01 | 2007-10-18 | 株式会社カルディオ | 三次元組織構造体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020001577A1 (en) * | 2000-06-30 | 2002-01-03 | Axel Haverich | Use of cells with the ability to generate excitation within a cell preparation |
US8889122B2 (en) * | 2005-05-09 | 2014-11-18 | Mytogen, Inc. | Cellular cardiomyoplasty as supportive therapy in patients with heart disease |
US7534607B1 (en) * | 2005-12-27 | 2009-05-19 | Industrial Technology Research Institute | Method of producing cardiomyocytes from mesenchymal stem cells |
WO2007138577A2 (en) * | 2006-05-25 | 2007-12-06 | Yeda Research And Development Co. Ltd. | Methods of generating a neural tissue using muscle-derived cells |
-
2011
- 2011-08-17 JP JP2012529601A patent/JP5657674B2/ja active Active
- 2011-08-17 CN CN201180021599.1A patent/CN102869988B/zh active Active
- 2011-08-17 WO PCT/JP2011/068587 patent/WO2012023562A1/ja active Application Filing
- 2011-08-17 EP EP11818203.9A patent/EP2607898B1/en active Active
-
2013
- 2013-02-14 US US13/766,833 patent/US9909161B2/en active Active
-
2018
- 2018-02-20 US US15/900,411 patent/US20180171376A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007528755A (ja) * | 2003-08-01 | 2007-10-18 | 株式会社カルディオ | 三次元組織構造体 |
Non-Patent Citations (3)
Title |
---|
FRANCIS D. PAGANI ET AL: "Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 41, no. 5, JPN6014031127, 5 March 2003 (2003-03-05), pages 879 - 888, XP002316437, ISSN: 0002862425, DOI: 10.1016/S0735-1097(03)00081-0 * |
関谷直純 ほか: "自己筋芽細胞シートを用いた心筋再生療法", 循環器専門医, vol. 16, no. 2, JPN6011058192, 25 September 2008 (2008-09-25), pages 245 - 251, ISSN: 0002939290 * |
首藤恭広 ほか: "筋芽細胞と脂肪由来間葉系細胞を併用した細胞シートによるラット慢性期心筋梗塞モデルに対する心筋再生効果", GEN. THORAC. CARDIOVASC. SURG., vol. 57, JPN6011058191, 10 September 2009 (2009-09-10), pages 488, ISSN: 0002939289 * |
Also Published As
Publication number | Publication date |
---|---|
EP2607898A1 (en) | 2013-06-26 |
WO2012023562A1 (ja) | 2012-02-23 |
US20130157305A1 (en) | 2013-06-20 |
JP5657674B2 (ja) | 2015-01-21 |
EP2607898A4 (en) | 2014-03-05 |
US20180171376A1 (en) | 2018-06-21 |
EP2607898B1 (en) | 2016-01-20 |
CN102869988A (zh) | 2013-01-09 |
US9909161B2 (en) | 2018-03-06 |
CN102869988B (zh) | 2015-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Franco‐Barraza et al. | Preparation of extracellular matrices produced by cultured and primary fibroblasts | |
US20210132045A1 (en) | Fibroblast growth patterns for diagnosis of alzheimer's disease | |
JP5243535B2 (ja) | イメージ内のウィルス顆粒を集計及び区分する方法 | |
JP6569672B2 (ja) | 観察装置、観察方法、観察システム、そのプログラム、および細胞の製造方法 | |
Sampaio-Pinto et al. | Neonatal apex resection triggers cardiomyocyte proliferation, neovascularization and functional recovery despite local fibrosis | |
Di Iorio et al. | Q‐FIHC: Quantification of fluorescence immunohistochemistry to analyse p63 isoforms and cell cycle phases in human limbal stem cells | |
CN114359899B (zh) | 细胞共培养模型及细胞模型构建方法、计算机设备及存储介质 | |
Broughton et al. | Cardiac interstitial tetraploid cells can escape replicative senescence in rodents but not large mammals | |
JP2019162118A (ja) | 有足突起培養物およびその使用 | |
JP5657674B2 (ja) | 移植片の評価方法 | |
Rosethorne et al. | Airway remodeling disease: primary human structural cells and phenotypic and pathway assays to identify targets with potential to prevent or reverse remodeling | |
WO2006095896A1 (ja) | 培養細胞監視システム | |
US20110312016A1 (en) | Method for Evaluating Immunosuppression | |
JP2012223104A (ja) | 誘導多能性幹細胞の識別方法 | |
EP3812467A1 (en) | Method for analyzing behavior of cells, and use thereof | |
EP3680327A1 (en) | Abnormal cardiac rhythm myocardial model and method for producing same, agent for forming abnormal cardiac rhythm myocardial model, and method for evaluating drug efficacy of heart disease therapeutic | |
Riedl et al. | Functional label-free assessment of fibroblast differentiation in 3D collagen-I-matrices using particle image velocimetry | |
Weeratunga et al. | Temporo-spatial cellular atlas of the regenerating alveolar niche in idiopathic pulmonary fibrosis | |
US20230193187A1 (en) | System for determining multinucleated state of myoblast cells | |
Choi | Integrative and Scalable Pipeline for Multi-omic Characterization of Biological Tissues | |
Taghdiri | Developments and applications of tools for studying injury responses in the ischemic border zone | |
Broughton et al. | Tetraploidy in rodent cardiac stem cells confers enhanced biological properties | |
Sjölin et al. | Expression of Stem Cell Niche-Related Biomarkers at the Base of the Human Tricuspid Valve | |
Zhang et al. | A machine learning based approach for quantitative evaluation of cell migration in Transwell assays based on deformation characteristics | |
WO2020049642A1 (ja) | 細胞解析装置及び細胞解析方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140520 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20140623 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140702 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20140702 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20140710 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140822 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141017 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141020 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141118 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141126 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5657674 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |